India Crosses 80 Lakh HPV Vaccinations Under National Cervical Cancer Elimination Push

🗞️ Why in News On 11 September 2026, the Ministry of Health and Family Welfare (MoHFW) confirmed that India has crossed 80 lakh HPV vaccinations under the National HPV Vaccination Campaign, launched in February 2026. The campaign targets 14-year-old girls with a voluntary, free-of-cost, single-dose regimen requiring parental consent. Four states have crossed 100 per cent of their identified target cohort: Gujarat, Uttar Pradesh, Madhya Pradesh and Mizoram; Uttar Pradesh alone has vaccinated over 22 lakh girls.

The Campaign in One Table

The Cervical Cancer Burden

Cervical cancer is the fourth-most common cancer among women worldwide. In India, it is the second-most common cancer among women (after breast). The Global Cancer Observatory (GLOBOCAN) placed India’s annual new cases in the range of 1.25 lakh and annual deaths at approximately 77,000 in its most recent estimates. India accounts for roughly a quarter of global cervical-cancer deaths.

The causal pathway is well established: persistent infection with high-risk Human Papillomavirus (HPV), most notably types 16 and 18 (which together account for about 70 per cent of cervical cancers), drives cellular transformation in the transformation zone of the cervix over one to two decades. HPV also causes anogenital and oropharyngeal cancers in both sexes.

The Vaccine: Gardasil-4, and the Cervavac Backdrop

The vaccine deployed in the campaign is Gardasil-4, the quadrivalent HPV vaccine manufactured by Merck / MSD and procured for India through the Gavi, the Vaccine Alliance partnership. Gardasil-4 protects against HPV types 6, 11, 16 and 18, the last two of which cause about 70 per cent of cervical cancers.

Alongside this, India has an indigenous quadrivalent HPV vaccine, Cervavac, developed by the Serum Institute of India (SII) with support from the Department of Biotechnology (DBT). Cervavac received DCGI market authorisation in July 2022 and was commercially launched in early 2023. It is not the vaccine chosen for the current national campaign; WHO prequalification is a prerequisite for procurement through the Gavi channel and Cervavac has been progressing through that pathway.

The single-dose schedule used in the campaign follows the WHO Strategic Advisory Group of Experts (SAGE) 2022 recommendation, which endorsed a single-dose regimen (previously two doses) as effective for adolescent HPV vaccination, based on evidence from several countries. The single-dose approach halves the logistical burden of the campaign.

The WHO Elimination Framework: 90-70-90

WHO launched a Global Strategy to Accelerate the Elimination of Cervical Cancer in 2020. It defines elimination as a threshold rather than eradication: reducing incidence to fewer than 4 per 100,000 women per year, sustained.

The 2030 interim targets, known as 90-70-90:

India’s 2026 campaign is aimed at the first pillar. The second and third pillars, HPV DNA-based screening and access to treatment for pre-cancer and invasive cancer, are addressed through the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD) operating through Health and Wellness Centres (renamed Ayushman Arogya Mandirs).

Where the Campaign Fits: India’s Immunisation Architecture

The Universal Immunization Programme (UIP), launched in 1985 by the Government of India, provides free vaccination against 12 vaccine-preventable diseases. The HPV vaccine has been added to the campaign portfolio delivered through the UIP infrastructure, using schools and community sessions for the 14-year-old cohort.

Mission Indradhanush (2014) and Intensified Mission Indradhanush (IMI) rounds address partially and unimmunised children. U-WIN is the digital platform that has replaced Co-WIN for routine immunisation tracking.

UPSC Relevance

GS Paper 2. Health-sector schemes; welfare-delivery architecture; institutional design for public health.

GS Paper 3. Biotechnology; indigenous vaccine development; public-health infrastructure.

The Mains framing. The HPV campaign is India’s first at-scale test of a single-dose adolescent-cancer-prevention vaccine deployed through the UIP and school system, using an indigenously developed product. The success indicators are three: (1) coverage of the 14-year-old cohort (with 80 lakh already vaccinated), (2) equity across states and social groups, and (3) the campaign’s ability to move to a permanent UIP schedule rather than a one-off drive.

A question worth preparing. “Assess India’s National HPV Vaccination Campaign as a component of the WHO’s 90-70-90 cervical cancer elimination strategy. Discuss its coverage design, indigenous-vaccine base, and the remaining challenges. (250 words)”

The counterpoint to hold. Vaccination alone will not eliminate cervical cancer within the current cohort of adult women; screening and treatment for the 20-45 age group remain the harder implementation problem. Vaccine procurement, cold-chain integrity, adolescent consent architecture and the rural-urban equity gap in coverage are the operational issues to watch.

📌 Facts Corner, Knowledgepedia

Prelims, statement-ready facts:

• India has crossed 80 lakh HPV vaccinations as of 11 September 2026 under the National HPV Vaccination Campaign, launched February 2026.
• Target cohort: 14-year-old girls; regimen: voluntary, free-of-cost, single-dose, with parental consent.
• Campaign vaccine: Gardasil-4 (quadrivalent HPV vaccine, Merck / MSD), procured through the Gavi partnership, protecting against HPV types 6, 11, 16 and 18.
• India also has an indigenous quadrivalent HPV vaccine, Cervavac (Serum Institute of India, DBT-supported), which received DCGI market authorisation in July 2022; it is not the campaign vaccine but is progressing towards WHO prequalification.
• States that have crossed 100% of the identified target: Gujarat, Uttar Pradesh, Madhya Pradesh, Mizoram; UP has vaccinated over 22 lakh girls.
• WHO cervical-cancer elimination targets (by 2030): 90-70-90 (90% vaccination, 70% screening, 90% treatment of identified disease).
• Cervical cancer is the second-most common cancer among Indian women (after breast).
• HPV types 16 and 18 cause approximately 70 per cent of cervical cancers.
• Universal Immunization Programme (UIP) was launched in 1985 and covers 12 vaccine-preventable diseases.

Prelims, the traps:

• The campaign uses Gardasil-4 (Merck / MSD), procured through Gavi. Cervavac (SII) is a separate indigenously developed quadrivalent option, not the campaign vaccine.
• Cervavac is quadrivalent (types 6, 11, 16, 18), NOT bivalent or nine-valent; a WHO prequalification requirement governs procurement through the Gavi channel.
• WHO’s SAGE recommendation for single-dose HPV vaccination was in 2022, superseding the earlier two-dose schedule for adolescents.
• WHO defines “elimination” of cervical cancer as fewer than 4 per 100,000 per year, NOT zero cases; it is a threshold, not eradication.
• India’s cervical-cancer incidence and mortality figures come from GLOBOCAN estimates; the National Cancer Registry Programme (NCRP, ICMR-NCDIR) provides Indian data.
• HPV also causes anogenital and oropharyngeal cancers in both sexes; the current campaign is female-only for cost-effectiveness targeting.

Mains, arguments and keywords:

• Elimination vs eradication distinction: threshold-based public-health goal.
• Indigenous vaccine development: SII, DBT, IP-lite pricing.
• Single-dose regimen: logistical halving of campaign burden; equity implications for hard-to-reach areas.
• The 90-70-90 as three-legged stool: vaccination alone cannot deliver elimination; screening and treatment gaps remain binding.
• Federalism: state-wise variation in coverage; UP as coverage leader; equity challenge in northeast beyond Mizoram.
• Keywords: Gardasil-4, Gavi, Cervavac, qHPV, SAGE, 90-70-90, UIP, U-WIN, NP-NCD, Ayushman Arogya Mandir, HPV 16/18, transformation zone.

Interview, be ready for:

• “Why 14-year-olds and not younger?” Immunological response is strong across the 9-14 range; India chose 14 to align with school-based delivery through Class 9, which minimises drop-out and consent friction.
• “Why is elimination defined as fewer than 4 per 100,000, not zero?” Zero is technically infeasible; the threshold captures a point below which cervical cancer ceases to be a public-health problem while acknowledging residual cases from earlier HPV cohorts.
• “How does Cervavac compare with Gardasil and Cervarix?” Cervavac is quadrivalent (types 6, 11, 16, 18), like Gardasil-4. Gardasil-9 covers nine types; Cervarix is bivalent (16, 18). Cervavac’s cost advantage enables population-scale deployment.
• “What is the U-WIN platform?” A digital immunisation record system replacing Co-WIN for routine (non-COVID) immunisation, integrating with UIP records, birth registration and Aadhaar (voluntary).

Sources: MoHFW, PIB, WHO, Serum Institute of India, GKToday

Source: India Crosses 80 Lakh HPV Vaccinations Under National Cervical Cancer Elimination Push — Ujiyari.com | Free UPSC & State PCS Current Affairs